| Title |
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
|
|---|---|
| Published in |
Cancer Discovery, September 2021
|
| DOI | 10.1158/2159-8290.cd-21-0697 |
| Pubmed ID | |
| Authors |
Funda Meric-Bernstam, Rastislav Bahleda, Cinta Hierro, Marc Sanson, John Bridgewater, Hendrik-Tobias Arkenau, Ben Tran, Robin Kate Kelley, Joon Oh Park, Milind Javle, Yaohua He, Karim A. Benhadji, Lipika Goyal |
X Demographics
The data shown below were collected from the profiles of 53 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 21 | 40% |
| Uganda | 2 | 4% |
| Turkey | 2 | 4% |
| Germany | 2 | 4% |
| Belgium | 2 | 4% |
| United Kingdom | 2 | 4% |
| Brazil | 2 | 4% |
| Spain | 1 | 2% |
| Canada | 1 | 2% |
| Other | 4 | 8% |
| Unknown | 14 | 26% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 31 | 58% |
| Practitioners (doctors, other healthcare professionals) | 9 | 17% |
| Scientists | 9 | 17% |
| Science communicators (journalists, bloggers, editors) | 4 | 8% |
Mendeley readers
The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 83 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 12% |
| Other | 9 | 11% |
| Student > Bachelor | 6 | 7% |
| Student > Postgraduate | 4 | 5% |
| Student > Master | 4 | 5% |
| Other | 6 | 7% |
| Unknown | 44 | 53% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 19% |
| Biochemistry, Genetics and Molecular Biology | 11 | 13% |
| Arts and Humanities | 2 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
| Chemistry | 2 | 2% |
| Other | 3 | 4% |
| Unknown | 47 | 57% |
Attention Score in Context
This research output has an Altmetric Attention Score of 37. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 September 2023.
All research outputs
#1,117,640
of 25,837,817 outputs
Outputs from Cancer Discovery
#574
of 4,151 outputs
Outputs of similar age
#25,945
of 437,950 outputs
Outputs of similar age from Cancer Discovery
#16
of 60 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,151 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.2. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,950 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 60 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.